|
|
|
Volumn 87, Issue 5, 2001, Pages
|
|
Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial;Doxorubicina e paclitaxel versus 5-fluorouracile, doxorubicina e ciclofosfamide come trattamento di prima linea in donne affette da carcinoma mammario metastatico: risultati finali di uno studio multicentrico randomizzato di fase III.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAF PROTOCOL;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FLUOROURACIL;
PACLITAXEL;
ARTICLE;
BREAST TUMOR;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
FEMALE;
HUMAN;
MULTICENTER STUDY;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FEMALE;
FLUOROURACIL;
HUMANS;
MULTICENTER STUDIES;
PACLITAXEL;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 0035462751
PISSN: 03008916
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
